Table 2. Risk factors predicting CRT resistance.
| Variables | Univariate | Multivariate | ||
| CRT resistance rate (%) | P value | RR | P value | |
| Gender | 0.28 | 0.062 | ||
| Female | 80.0 | 7.79 | ||
| Male | 60.0 | 1 | ||
| Age | 0.17 | |||
| <71 | 81.3 | |||
| ≥71 | 57.9 | |||
| Clinical T stage | 0.28 | |||
| T2 | 57.1 | |||
| T3-4a | 76.2 | |||
| Tumor size | 0.075 | |||
| <5 cm | 52.9 | |||
| ≥5 cm | 83.3 | |||
| Multifocality | 0.71 | |||
| No | 75.0 | |||
| Yes | 65.2 | |||
| Presence of CIS | 1.00 | |||
| No | 67.9 | |||
| Yes | 71.4 | |||
| Presence of hydronephrosis | 0.056 | 0.038 | ||
| No | 56.5 | 1 | ||
| Yes | 91.7 | 14.3 | ||
| ErbB2 | 0.003 | 0.014 | ||
| Negative (<20%) | 46.7 | 1 | ||
| Positive (≥20%) | 85.0 | 11.8 | ||
| NFκB | 0.055 | 0.024 | ||
| Negative (<20%) | 56.5 | 1 | ||
| Positive (≥20%) | 91.7 | 15.4 | ||
| p53 | 0.45 | |||
| Negative (<10%) | 80.0 | |||
| Positive (≥10%) | 64.0 | |||
| Survivin | 1.00 | |||
| Negative (<20%) | 71.4 | |||
| Positive (≥20%) | 67.9 | |||
| Combination of erbB2 and NFκB | <0.0001 | - | ||
| Dual negative | 11.1 | |||
| Single or dual positive | 88.5 | |||
RR, relative risk.